Mannitol inhalation diagnostic/theranostic - Pharmaxis

Drug Profile

Mannitol inhalation diagnostic/theranostic - Pharmaxis

Alternative Names: Aridol; Osmohale

Latest Information Update: 23 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmaxis
  • Developer Allertec Hellas; Nigaard Pharma; Pharmaxis; Praxis Pharmaceuticals; Trimedal
  • Class Diagnostic agents; Small molecules; Sugar alcohols
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Aug 2018 Pharmaxis plans to relaunch Aridol® into the US market later in 2018 via Methapharm, its exclusive distribution partner
  • 24 Jun 2018 Biomarkers information updated
  • 20 Jul 2015 Nigaard Pharma has been acquired by Zambon SpA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top